MicroRNA‑423‑5p targets O‑GlcNAc transferase to induce apoptosis in cardiomyocytes

Luo,Peng; He,Tao; Jiang,Rongjian; Li,Gang

doi:10.3892/mmr.2015.3491

MicroRNA‑423‑5p targets O‑GlcNAc transferase to induce apoptosis in cardiomyocytes

Authors:
- Peng Luo
- Tao He
- Rongjian Jiang
- Gang Li
View Affiliations

Affiliations: Department of Cardiology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072, P.R. China
Published online on: March 13, 2015 https://doi.org/10.3892/mmr.2015.3491
Pages: 1163-1168

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Congestive heart failure (CHF) remains the single most prevalent cause of mortality and morbidity; therefore, the identification of novel biomarkers is required for the diagnosis of CHF. The aim of the present study was to examine whether microRNA (miR)‑423‑5p is a novel biomarker for CHF, which was defined by the circulatory biomarker pro‑brain natriuretic peptide (BNP). Samples of plasma from patients with CHF and healthy controls were collected and used for quantitative polymerase chain reaction analysis. In addition, the O‑GlcNAc transferase (OGT) 3' untranslated region was cloned and used for a luciferase assay. The effects of the expression of miR‑423‑5p in cardiomyocytes were determined using western blotting and terminal deoxynucleotidyl transferase‑deoxyuridine triphosphate nick‑end labeling analyses. The results demonstrated that miR‑423‑5p was associated with CHF and the expression levels of proBNP; in addition, OGT was found to be a direct target of miR‑423‑5p. The expression of miR‑423‑5p significantly regulated the expression of OGT and its associated downstream targets and induced apoptosis in the cardiomyocytes. Therefore, the results of the present study indicated that miR‑423‑5p was involved in CHF via the direct targeting of OGT and the induction of apoptosis in cardiomyocytes.

View Figures

View References

1	Dassanayaka S and Jones SP: O-GlcNAc and the cardiovascular system. Pharmacol Ther. 142:62–71. 2013. View Article : Google Scholar : PubMed/NCBI
2	Shaf R, Iyer SP, Ellies LG, O’Donnell N, Marek KW, Chui D, et al: The O-GlcNAc transferase gene resides on the X chromosome and is essential for embryonic stem cell viability and mouse ontogeny. Proc Natl Acad Sci USA. 97:5735–5739. 2000. View Article : Google Scholar
3	Watson LJ, Facundo HT, Ngoh GA, Ameen M, Brainard RE, Lemma KM, et al: O-linked beta-N-acetylglucosamine transferase is indispensable in the failing heart. Proc Natl Acad Sci USA. 107:17797–17802. 2010. View Article : Google Scholar
4	Mann DL and Bristow MR: Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 111:2837–2849. 2005. View Article : Google Scholar : PubMed/NCBI
5	Seidman JG and Seidman C: The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell. 104:557–567. 2001. View Article : Google Scholar : PubMed/NCBI
6	Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, et al: NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 27:330–337. 2006. View Article : Google Scholar
7	van Kimmenade RR, Pinto YM and Januzzi JL Jr: Importance and interpretation of intermediate (gray zone) amino-terminal pro-B-type natriuretic peptide concentrations. Am J Cardiol. 101:39–42. 2008. View Article : Google Scholar : PubMed/NCBI
8	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
9	van Rooij E, Marshall WS and Olson EN: Toward microRNA-based therapeutics for heart disease: the sense in antisense. Circ Res. 103:919–928. 2008. View Article : Google Scholar : PubMed/NCBI
10	Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
11	Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, et al: Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 141:672–675. 2008. View Article : Google Scholar : PubMed/NCBI
12	Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
13	Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, et al: MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation. 116:258–267. 2007. View Article : Google Scholar : PubMed/NCBI
14	Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE, et al: MiR423-5p as a circulating biomarker for heart failure. Circ Res. 106:1035–1039. 2010. View Article : Google Scholar : PubMed/NCBI
15	Bauters C, Kumarswamy R, Holzmann A, Bretthauer J, Anker SD, Pinet F, et al: Circulating miR-133a and miR-423-5p fail as biomarkers for left ventricular remodeling after myocardial infarction. Int J Cardiol. 168:1837–1840. 2013. View Article : Google Scholar : PubMed/NCBI
16	Tutarel O, Dangwal S, Bretthauer J, Westhoff-Bleck M, Roentgen P, Anker SD, et al: Circulating miR-423_5p fails as a biomarker for systemic ventricular function in adults after atrial repair for transposition of the great arteries. Int J Cardiol. 167:63–66. 2013. View Article : Google Scholar
17	Fekete MR, McBride WH and Pajonk F: Anthracyclines, proteasome activity and multi-drug-resistance. BMC Cancer. 5:1142005. View Article : Google Scholar : PubMed/NCBI
18	Rosamond WD, Chang PP, Baggett C, et al: Classification of heart failure in the atherosclerosis risk in communities (ARIC) study: A comparsion of diagnostic criteria. Circ Heart Fail. 5:152–159. 2012. View Article : Google Scholar : PubMed/NCBI
19	Yang C, Liu Z, Liu K and Yang P: Mechanisms of Ghrelin anti-heart failure: Inhibition of Ang II-induced cardiomyocyte apoptosis by down-regulating AT1R expression. PLoS One. 9:e857852014. View Article : Google Scholar : PubMed/NCBI
20	Ai J, Zhang R, Li Y, Pu J, Lu Y, Jiao J, et al: Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun. 391:73–77. 2010. View Article : Google Scholar
21	Ji X, Takahashi R, Hiura Y, Hirokawa G, Fukushima Y and Iwai N: Plasma miR-208 as a biomarker of myocardial injury. Clin Chem. 55:1944–1949. 2009. View Article : Google Scholar : PubMed/NCBI
22	Dassanayaka S and Jones SP: O-GlcNAc and the cardiovascular system. Pharmacol Ther. 142:62–71. 2014. View Article : Google Scholar :
23	Shaf R, Iyer SP, Ellies LG, O’Donnell N, Marek KW, Chui D, et al: The O-GlcNAc transferase gene resides on the X chromosome and is essential for embryonic stem cell viability and mouse ontogeny. Proc Natl Acad Sci USA. 97:5735–5739. 2000. View Article : Google Scholar
24	Watson LJ, Facundo HT, Ngoh GA, Ameen M, Brainard RE, Lemma KM, et al: O-linked beta-N-acetylglucosamine transferase is indispensable in the failing heart. Proc Natl Acad Sci USA. 107:17797–17802. 2010. View Article : Google Scholar
25	Hardie DG: AMPK and Raptor: matching cell growth to energy supply. Mol Cell. 30:263–265. 2008. View Article : Google Scholar : PubMed/NCBI
26	Zou MH and Wu Y: AMP-activated protein kinase activation as a strategy for protecting vascular endothelial function. Clin Exp Pharmacol Physiol. 35:535–545. 2008. View Article : Google Scholar : PubMed/NCBI
27	Xu J, Wang S, Viollet B and Zou MH: Regulation of the proteasome by AMPK in endothelial cells: the role of O-GlcNAc transferase (OGT). PloS one. 7:e367172012. View Article : Google Scholar : PubMed/NCBI